Congenital Afibrinogenemia
3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
GrifolsNEW YORK, NY
2 programs1
1
FIB GrifolsPhase 31 trial
Human Plasma-Derived Fibrinogen ConcentratePhase 1/21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
GrifolsFIB Grifols
Biotest PharmaceuticalsBT524
GrifolsHuman Plasma-Derived Fibrinogen Concentrate
Clinical Trials (3)
FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis
Start: Dec 2023Est. completion: Mar 2025
Phase 3Withdrawn
Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency
Start: Mar 2013Est. completion: Nov 2020
Phase 3Completed
Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia
Start: Jul 2016Est. completion: Nov 2019
Phase 1/2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space